News

Development efforts focused on next generation oligonucleotides to treat cancer capitalizing on long-standing experience in TGF-ß.

Researchers at Kanazawa University have demonstrated a technique that allows direct functionalization of alkenes without the need for metallic reagents, photolysis or extreme reaction conditions.

The acquisition of NanoSight by Malvern Instruments was completed on Friday 27 September.

Patent valid until at least 2031.

MIT’s Institute for Medical Engineering and Science brings many tools to the quest for new disease treatments and diagnostic devices.

A nationwide group of institutions that conducts clinical trials has been awarded nine contracts to strengthen and broaden the scope of its research.

Contract with CDC for the supply of VIGIV extended by 18 months.

Agreement with Takeda to license back previously granted European rights to Catena® in DMD.

Findings are published in the Journal of the American Medical Association.

Continuous-flow synthesis methods offer several advantages over traditional batch methods.